Background

To assess reactivation after initial intravitreal injection of ranibizumab (IVR) for type 1 retinopathy of prematurity (ROP) or worse and the outcome following reinjection of ranibizumab for this reactivation.

Methods

This retrospective study was performed on infants screened for ROP between March 2013 and February 2020 in Mansoura University Children Hospital, Mansoura, Egypt. Infants treated with ranibizumab 0.25 mg/0.025 mL were identified for review of their clinical outcomes. Data of infants with reactivation and IVR re-injection were analysed.

Results

A total of 2318 infants were screened for ROP, 115 (5%) infants (216 eyes) with a mean gestational age of 30 ± 2.5 weeks and mean birth weight of 1290 ± 355.2 g received IVR at mean postmenstrual age (PMA) of 38 ± 3.1 weeks. All treated eyes demonstrated initial regression of ROP. However, ROP reactivation occurred in 5 (2.3%) eyes of 3 patients, at an average of 9.6 ± 2.9 weeks after treatment. None of these eyes had retinal detachment. A second dose IVR was administered and all five eyes showed regression with complete retinal vascularisation, at a mean PMA of 60 ± 5.1 weeks.

Conclusions

IVR is beneficial as an initial and subsequent treatment for type 1 ROP or APROP. A long-term follow-up until complete retinal vascularisation is recommended to avoid disease reactivation.

中文翻译：

---

重新注射雷珠单抗治疗早产儿视网膜病变的临床结果

背景

评估初始玻璃体内注射雷珠单抗 (IVR) 后对 1 型早产儿视网膜病变 (ROP) 或更严重的再激活以及再注射雷珠单抗后的结果。

方法

这项回顾性研究是在 2013 年 3 月至 2020 年 2 月期间在埃及曼苏拉的曼苏拉大学儿童医院对接受 ROP 筛查的婴儿进行的。确定了接受雷珠单抗 0.25 mg/0.025 mL 治疗的婴儿，以评估其临床结果。分析了重新激活和 IVR 再注射婴儿的数据。

结果

共有 2318 名婴儿接受了 ROP 筛查，115 名（5%）婴儿（216 只眼）平均孕周为 30 ± 2.5 周，平均出生体重为 1290 ± 355.2 g，在平均经后年龄（PMA）为 38 岁时接受了 IVR ± 3.1 周。所有治疗的眼睛都表现出ROP的初始消退。然而，在治疗后平均 9.6 ± 2.9 周，3 名患者的 5 只（2.3%）眼发生了 ROP 再激活。这些眼睛都没有视网膜脱离。给予第二剂 IVR，所有五只眼睛均显示消退，视网膜血管形成完全，平均 PMA 为 60 ± 5.1 周。

结论

IVR 作为 1 型 ROP 或 APROP 的初始和后续治疗是有益的。建议进行长期随访直至视网膜血管形成完全，以避免疾病重新激活。